12:00 AM
 | 
Jun 02, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DMOT4039A: Phase I data

An open-label, dose-escalation, U.S. and Dutch Phase I trial in 49 patients with unresectable pancreatic cancer or platinum-resistant ovarian cancer showed that 2.4 mg/kg IV DMOT4039A every 3 weeks led to 4 partial responses. Additionally, 1 pancreatic cancer patient without a RECIST response had a >50% reduction from baseline in CA19-9 levels and 7 ovarian...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >